{"filings":[{"id":2943916,"accession_number":"0001193125-26-395031","cik":1839970,"company_name":"BlossomHill Therapeutics, Inc.","ticker":"BLSM","form_type":"8-K","filed_at":"2026-09-18T11:15:07+00:00","items":["2.02","9.01"],"status":"ready","headline":"BlossomHill Q2 net loss $23.8M; IPO raises $168.3M; FDA Fast Track for lung cancer drug","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $23.8M ($8.75/share) vs $13.2M ($5.51/share) in Q2 2025.","R&D expenses $21.4M (up from $12.5M); G&A $3.3M (up from $1.6M).","Cash $95.4M at June 30; August IPO gross proceeds $168.3M fund ops into Q2 2028.","FDA Fast Track granted for BH-30643 in EGFR C797S-positive NSCLC after 3rd-gen TKI.","Phase 1 SOLARA data: 45% ORR, 88% DCR in C797S-resistant patients; more milestones ahead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2862396,"accession_number":"0001193125-26-391328","cik":1839970,"company_name":"BlossomHill Therapeutics, Inc.","ticker":"BLSM","form_type":"8-K","filed_at":"2026-09-15T11:30:06+00:00","items":["7.01","9.01"],"status":"ready","headline":"BlossomHill reports 45% ORR for BH-30643 in EGFR C797S-positive NSCLC from SOLARA trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 45% (18/40) and DCR 88% (35/40) in EGFR C797S-positive NSCLC patients with prior EGFR inhibitor resistance, ± T790M.","63% (25/40) remained on treatment at median follow-up 6.9 months; 98% had prior osimertinib, 35% concurrent T790M.","Safety (n=174, 40/50/60 mg BID): treatment-related dose reductions 9%, discontinuations 3%; common AE bilirubin elevation.","Plans global Phase 2 targeting EGFR C797S-positive NSCLC in Q1 2027; FDA Fast Track designation previously granted.","Activity seen across pretreated population: median 2 prior lines; 53% prior chemo/ADC; 53% history of brain metastases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2162041,"accession_number":"0001193125-26-342316","cik":1839970,"company_name":"BlossomHill Therapeutics, Inc.","ticker":"BLSM","form_type":"8-K","filed_at":"2026-08-10T20:01:18+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"BlossomHill Therapeutics completes IPO of 9.375M shares at $16.00, gross proceeds ~$150M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed Aug 10, 2026; 9,375,000 shares sold at $16.00 per share.","Gross proceeds approximately $150.0M before underwriting discounts and expenses.","Amended and restated certificate of incorporation and bylaws effective Aug 10, 2026.","Stock trades on Nasdaq Global Select Market under ticker BLSM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":null,"market_cap_bucket":null,"market_cap_source":null,"market_cap_as_of_date":null,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}